NCT06205732

A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.

Retrospective Study and Construction of a Prediction Model for Patients With Intermediate and Advanced Liver Cancer Treated With TACE Combined With Immunotherapy and Targeted Therapy

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 100 (estimated)
• Sponsor: Qianfoshan Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

To evaluate the effectiveness of TACE combined with immunotherapy and targeted therapy versus TACE alone in patients with intermediate and advanced liver cancer.

Detailed description

To evaluate the efficacy and safety of TACE combined with immunotherapy and targeted therapy in patients with intermediate and advanced liver cancer. Explore the factors affecting the prognosis of liver cancer treated with TACE combined with immunotherapy and targeted therapy and establish a specific individualized prognostic score and risk stratification model.

Conditions

• Carcinoma, Hepatocellular

Interventions

Type	Name	Description
OTHER	Immunotherapy, targeted therapy.	Immunotherapy (sintilimab, camrelizumab, tislelizumab, atezolizumab, durvalumab, cardenilumab, and pembrolizumab); targeted therapy (apatinib, lenvatinib, sorafenib, and regorafenib).

Timeline

• Start date: 2024-01-01
• Primary completion: 2024-12-01
• Completion: 2024-12-01
• First posted: 2024-01-16
• Last updated: 2024-01-16

Locations

1 site across 1 country: China